Spexis AG, a clinical-stage biopharmaceutical company focused on rare diseases and oncology, announced that it has engaged Maxim Group LLC as a financial advisor to assist in the evaluation of strategic alternatives and fundraising opportunities.
Spexis AG, a clinical-stage biopharmaceutical company focused on rare diseases and oncology, announced that it has engaged Maxim Group LLC as a financial advisor to assist in the evaluation of strategic alternatives and fundraising opportunities.